ReviewMedicine2025
Follicular dendritic cell sarcoma of the stomach in a young male: A rare case report and literature review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence-driven gastrointestinal functional assessment: multimodal imaging, digital biomarkers, and real-time monitoring.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleFollicular dendritic cell sarcoma (FDCS) is an exceptionally rare mesenchymal tumor, with gastric involvement being scarcely reported (only 7 prior cases). This case highlights the diagnostic challenges and underscores the importance of multimodal imaging in identifying this malignancy, particularly in extra-nodal sites like the stomach. PATIENT CONCERNS: A 25-year-old male presented with acute abdominal pain and a palpable mid-abdominal mass. He denied weight loss, fever, or gastrointestinal symptoms. Laboratory tests revealed elevated squamous cell carcinoma-related antigen (3.6 ng/mL). DIAGNOSES: Contrast-enhanced abdominal computed tomography (CT) revealed a 68 × 47 × 91 mm soft tissue mass in the gastric antrum, vascularized by the left gastric artery. Positron emission tomography/CT demonstrated intense FDG uptake (SUVmax 25.48). Magnetic resonance images showed a T1-isointense, T2-hypointense mass with diffusion restriction (diffusion weighted imaging hyperintensity, low ADC) and moderate arterial enhancement. Endoscopy identified a submucosal gastric lesion. Histopathology confirmed FDCS via spindle/epithelioid cells, neutrophils, and immunohistochemistry (CD23/CD35/CD31+, S100/CK-).
interventionsThe patient underwent distal gastrectomy with Roux-en-Y gastrojejunostomy. Intraoperatively, the tumor was resected with clear margins, preserving gastric function. No lymph node metastasis was observed. OUTCOMES: Postoperative recovery was uneventful. Pathology confirmed a 9 cm FDCS without necrosis or calcifications. Immunohistochemistry validated the diagnosis. No adjuvant therapy was administered, and the patient remained recurrence-free during follow-up. LESSONS: Gastric FDCS is easily misdiagnosed as gastrointestinal stromal tumor (GIST) or Castleman disease due to overlapping imaging features. Multimodal imaging (CT, MRI, positron emission tomography/CT) combined with histopathology is critical for accurate diagnosis. Radical surgery remains the cornerstone of treatment, emphasizing the need for wide resection to minimize recurrence. This case provides the first comprehensive imaging characterization of gastric FDCS, enhancing awareness and diagnostic precision for this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.